ALK and non-small cell lung carcinoma: A dynamic sequencing of circulating tumor DNA (ctDNA) in ensartinib-resistant ALK+ NSCLC patients revealed that ALK-dependent resistance mechanisms of ensartinib were mainly due to G1269A, G1202R, and E1210K mutations (74).